ELOX - Company ID 0001035354
The table below shows Eloxx Pharmaceuticals, Inc.'s income statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $0.00 | $6.36M | $0.00 | - | - | - |
| Cost of revenue | - | - | - | - | - | - |
| Gross profit | - | - | - | - | - | - |
| R&D | - | - | - | - | - | $14.59M |
| SG&A | $3.38M |
Eloxx Pharmaceuticals, Inc. reported annual revenue of $0.00 for fiscal year 2025. That is down 100.0% from $6.36M in fiscal 2024. Over the 7 fiscal years shown, annual revenue declined from $140.00K (FY 2010) to $0.00. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $5.25M |
| $8.69M |
| $10.69M |
| $20.45M |
| $14.85M |
| Operating income | -$6.44M | -$2.47M | -$17.29M | -$34.42M | -$66.02M | -$33.45M |
| Income tax | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net income | -$6.00M | -$3.14M | -$17.05M | -$36.06M | -$66.73M | -$34.58M |
| EPS (diluted) | -$5.34 | -$9.20 | -$72.98 | -$16.65 | -$38.15 | - |